Table 3.
Clinical Characteristics of the Individual Patients Included in the EoE Group
| Sex | Age, yr | Chief complaint | FSSG score | Eosinophil/HPF | Endoscopic findings | PPI-trial* | ||
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| Dose of PPI/day | Duration period, wk | |||||||
| 1 | M | 72 | Dysphagia | 16 | 18 | - | Rabeprazole 20 mg | 10 |
| 2 | M | 69 | Heartburn | 10 | 20 | - | Rabeprazole 20 mg | 16 |
| 3 | F | 56 | Epigastralgia | 11 | 40 | - | Rabeprazole 20 mg | 12 |
| 4 | F | 67 | Dysphagia | 22 | 30 | - | Lansoprazole 15 mg | 8 |
| 5 | F | 46 | Heartburn | 21 | 47 | Longitudinal furrows | Rabeprazole 20 mg | 8 |
| 6 | F | 75 | Heartburn | 31 | 40 | - | Rabeprazole 20 mg | 40 |
EoE, eosinophilic esophagitis; FSSG, frequency scale for the symptoms of gastroesophageal reflux disease; HPF, high-power field; PPI, proton pump inhibitor; M, male; F, female.
*
All patients in this table had already taken PPI for more than 8 weeks before enrollment in this study.